President & CEO, Atheris
Venom Evolution, Function, and Biomedical Applications
Reto Stöcklin is a scientific entrepreneur driven by innovation. He obtained his doctoral degree in medical biochemistry in the laboratories of Prof. Robin Offord in the Faculty of Medicine of Geneva in 1994. He excels in peptide chemistry, protein engineering, mass spectrometry, proteomics and bioinformatics. Reto innovated techniques of pharmacokinetics and metabolic studies of polypeptides by mass spectrometry. In parallel, he initiated toxinology studies and venom-based drug discovery programmes, created a unique database on venomous animals and their venoms, and subsequently pioneered peptide discovery and lead optimisation algorithms.
Dr Stöcklin leads Atheris SA, a research-driven biotech company he founded in Geneva back in 1995. Reto is also founder of FunZyme BioTechnologies SA, a biotech company created in 2005 that paved the way to the foundation of Amyra Biotech AG early 2013 that develops an enzyme-based therapy for the treatment of celiac disease (gluten intolerance) in which he acts as member of the board. He also is co-founder and board member of HiQScreen SàRL (high-throughput screening robots and services) and co-founded Activen SA (cosmetic ingredients). Back in 2000 he co-founded Swiss Proteomics Society, and in 2003 he pioneered the « Venomics Initiative ».
Reto has teaching functions in Geneva, Sion and Paris and he assisted the authorities for the classification of the Marquesas Islands to the UNESCO World Heritage Centre. Reto is member of the board of deputies of the Swiss “Helvetia-Patria Genossenschaft” and is organiser of the “Natural Peptides to Drugs - NP2D” international congress in Zermatt. He is also highly active as a consultant for several international institutions and companies. Over the past decade, he got deeply involved in marine biology and organised several scientific exploration missions around the world in which he took part, also as a scientific diver.